News | May 04, 2022

Heart Centre Rigshospitalet Copenhagen Celebrates 5,000 Robotic Cardiac Ablation Procedures

Denmark’s only robotic cardiac electrophysiology team is recognized for leading the world in treating the most heart rhythm patients using Stereotaxis’ advanced robotic technology.

Denmark’s only robotic cardiac electrophysiology team is recognized for leading the world in treating the most heart rhythm patients using Stereotaxis’ advanced robotic technology.

Image: Getty Images


May 4, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, celebrates the achievements of the highly skilled electrophysiology team at The Heart Centre Rigshospitalet, Copenhagen University Hospital for successfully completing more than 5,000 robotic cardiac ablation procedures using Denmark’s only robotic system for the treatment of heart rhythm disorders.

The Heart Centre Rigshospitalet at the University of Copenhagen is the leading user of advanced robotic technology for the treatment of cardiac arrhythmias among a hundred hospitals globally. Electrophysiologists use the technology to repair the electrical circuits of the heart in a minimally invasive procedure called cardiac ablation. Robotic technology is designed to provide increased precision and safety during the procedure. The experience of Rigshospitalet across 5,000 procedures demonstrates these benefits with exceptional procedure success and safety records. Since its installation in 2006, Rigshospitalet physicians have used Stereotaxis RMN technology to treat a broad range of patients including complex cases unsuitable for traditional treatments. Among the thousands of patients who have benefited from robotic ablation are pediatric and congenital heart disease patients.

Clinical cardiac electrophysiologist, Dr. Xu Chen, leads physicians in the world with the most robotic cardiac ablation procedures performed with Stereotaxis technology, having completed over 4,000 procedures. Dr. Chen has contributed to a significant body of clinical evidence on the use of robotics in electrophysiology by authoring and collaborating on 13 peer-reviewed studies.

“We are proud to celebrate this milestone and our contribution to improving patient care and advancing important technology for our field,” said Dr. Peter Karl Jacobsen, Head of Invasive Electrophysiology, ablation section, cardiology at Rigshospitalet.

“We have always pursued the best treatment for our patients and are glad we could help so many patients effectively and with great safety,” added Dr. Chen, Chief Physician and clinical cardiac electrophysiologist at Rigshospitalet.

Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest. Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation. Robotic cardiac ablation is performed using a soft magnetic catheter navigated inside the heart by a physician seated at a computer cockpit. The physician navigates the catheter using precise, robotically actuated magnets positioned on either side of the patient.

“We celebrate the Rigshospitalet electrophysiology team on this significant milestone,” said David Fischel, Stereotaxis Chairman and CEO. “To have treated 5,000 patients is an extraordinary feat. It reflects an outsized impact Rigshospitalet has had on advancing patient care, clinical science, and technology development in electrophysiology.”

For more information: www.rigshospitalet.dk/english/


Related Content

News

In a milestone for Broward Health in Ft. Lauderdale, Fla., Jose L. Baez-Escudero, M.D., chief of cardiology and ...

Home March 24, 2026
Home
News

Feb. 6, 2026 — Abbott has announced new clinical data from two late-breaking presentations at AF Symposium in Boston ...

Home February 06, 2026
Home
News

Jan. 20, 2026 — Abbott has received CE Mark in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat ...

Home January 22, 2026
Home
News

Jan. 20, 2026 — Kardium Inc. has announced the publication of the PULSAR clinical trial results in the Journal of the ...

Home January 21, 2026
Home
Feature | Kyle Hardner

Robotic Magnetic Navigation (RMN) emerged two decades ago as an alternative approach to performing complex ablation ...

Home January 09, 2026
Home
News

Jan. 6, 2026 — Stereotaxis, a supplier of surgical robotics for minimally invasive endovascular intervention, has ...

Home January 06, 2026
Home
News

Oct. 10, 2025 — Johnson & Johnson MedTech, in collaboration with the Heart Rhythm Clinical and Research Solutions, LLC ...

Home October 13, 2025
Home
News

Sept. 2, 2025 — Johnson & Johnson MedTech has announced acute safety and effectiveness results from the Varipure ...

Home September 05, 2025
Home
News

Sept. 3, 2025 — Kardium Inc. recently announced it has received pre-market approval (PMA) for the Globe Pulsed Field ...

Home September 03, 2025
Home
News

July 14, 2025  –  Johnson & Johnson MedTech has announced U.S. Food and Drug Administration (FDA) approval of an update ...

Home July 14, 2025
Home
Subscribe Now